IGM Biosciences pivoted to autoimmune disease, reducing R&D expenses. The company reported a net loss of $61.4 million. CEO ...

Stifel raised the firm’s price target on IGM Biosciences (IGMS) to $27 from $25 and keeps a Buy rating on the shares. The firm believes management’s ability to provide a preliminary mid-FY25 update ...

Igm Biosciences ( ($IGMS) ) has released its Q3 earnings. Here is a breakdown of the information Igm Biosciences presented to ...

Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on IGM Biosciences (IGMS – Research Report), retaining the price target of ...

Revenue exceeded analyst estimates by 113%. Earnings per share (EPS) missed analyst estimates by 24%. Looking ahead, revenue ...

The company’s 50 day moving average is $14.23 and its 200-day moving average is $10.74. IGM Biosciences has a 12 month low of $3.81 and a 12 month high of $22.50. The firm has a market cap of $1 ...

IGM Biosciences (NASDAQ:IGMS – Free Report) had its price objective increased by Royal Bank of Canada from $17.00 to $20.00 in a research note published on Friday morning, Benzinga reports.

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...

MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...

IGM Biosciences, Inc. (NASDAQ:IGMS), a biotechnology company focused on developing treatments for autoimmune diseases, has recently undergone a significant strategic shift that has caught the ...

IGM Biosciences, Inc. (NASDAQ:IGMS), a biotechnology company focused on developing treatments for autoimmune diseases, has recently undergone a significant strategic shift that has caught the ...